A Phase 4 interventional study of valsartan, amlodipine, HCTZ and Losartan, HCTZ followed by valsartan, amlodipine, HCTZ in Stage 2 Systolic Hypertension, sponsored by Novartis. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-07.
Sponsored by Novartis · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Isolated Systolic Hypertension with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Isolated Systolic Hypertension · United States.
Among the 13 studies in Isolated Systolic Hypertension with a site in United States, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2009, is one of 2 in phase 4, and was the 5th registered.
35 studies on the registry are indexed under Isolated Systolic Hypertension; 8 are open to participants now.
Browse Isolated Systolic Hypertension studies →3 of the 13 studies in Isolated Systolic Hypertension with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 18+
Orchestra BioMed, Inc · Sites in United States, Australia, Belgium and 12 more countries
Ages 18+
Marshall University · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Isolated Systolic Hypertension studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 488 is above the median of 100 across 31 interventional studies indexed under Isolated Systolic Hypertension.
Median enrollment 145 across the 12 interventional studies, 60 across the 1 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 13 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Novartis has 3 studies filed under Isolated Systolic Hypertension — fewer than ten, so there is no comparison to draw.
2 of the studies in Isolated Systolic Hypertension with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06059638Orchestra BioMed, IncBradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | 2026-12 |
| NCT07109739University of MinnesotaDose-Response Effects of Inspiratory Muscle Strength Training on Blood Pressure and Vascular Function | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Isolated Systolic Hypertension with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will compare the antihypertensive efficacy and safety of a valsartan/amlodipine-based treatment with a losartan-based treatment in patients with Stage 2 systolic hypertension (high blood pressure, mean systolic blood pressure greater than 160 and less than 200 mmHg).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study.
Drug: valsartan, amlodipine, HCTZ
Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study.
Drug: Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
Drug pages: Valsartan · Amlodipine · Hydrochlorothiazide
combination Valsartan/amlodipine160/5 mg tablet for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (6 weeks) of the study
Drug pages: Losartan · Hydrochlorothiazide · Valsartan · Amlodipine
losartan 100mg capsule for 3 weeks; losartan 100mg capsule +HCTZ 25 mg capsule for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (3 weeks) of the study
Change in Mean Sitting Systolic Blood Pressure After 6 Weeks
To compare the change from baseline in mean sitting systolic blood pressure (MSSBP) after 6 weeks of valsartan/amlodipine-based regimen with a losartan-based regimen in patients with Stage 2 systolic hypertension.
Time frame: Baseline to Week 6
Change in Mean Sitting Diastolic Blood Pressure After 6 Weeks
To compare the change from baseline in mean sitting diastolic blood pressure (MSDBP) after 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.
Time frame: Baseline to Week 6
Cumulative Percentage of Patients Achieving Blood Pressure Control
To compare the percentage of patients achieving blood pressure control (defined as patients achieving MSSBP \< 140 mmHg and MSDBP \< 90 mmHg) after 3 and 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.
Time frame: 3 and 6 weeks
Cumulative Percentage of Treatment Responders
To compare the percentage of treatment responders (defined as patients with MSSBP \< 140 mmHg or demonstrating a decrease from baseline of ≥ 20 mmHg) after 3 and 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.
Time frame: 3 and 6 weeks
Change in Mean Sitting Systolic and Diastolic Blood Pressure After 12 Weeks
To compare the change from baseline in MSSBP and MSDBP after 12 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.
Time frame: Baseline to week 12
Cumulative Percentage of Patients With Incidence of Peripheral Edema Before or at the Corresponding Visit
To assess the incidence of peripheral edema occurring with valsartan/amlodipine-based regimen versus losartan-based regimen in patients with Stage 2 systolic hypertension.
Time frame: 3, 6, 9 and 12 weeks
| Milestone | Valsartan/Amlodipine/HCTZ | Losartan/HCTZ |
|---|---|---|
| Started | 241 | 247 |
| Completed | 207 | 209 |
| Not completed | 34 | 38 |
| Withdrew: Adverse event | 16 | 10 |
| Withdrew: Abnormal test procedure results | 2 | 0 |
| Withdrew: Unsatisfactory therapeutic effects | 5 | 12 |
| Withdrew: Patient withdrew consent | 4 | 9 |
| Withdrew: Lost to follow-up | 6 | 5 |
| Withdrew: Protocol deviation | 1 | 2 |
To compare the change from baseline in mean sitting systolic blood pressure (MSSBP) after 6 weeks of valsartan/amlodipine-based regimen with a losartan-based regimen in patients with Stage 2 systolic hypertension.
| mmHg | Valsartan/Amlodipine/HCTZ | Losartan/HCTZ |
|---|---|---|
| Baseline | 166.8 ± 7.03 | 168.5 ± 9.03 |
| Week 6 | 135.5 ± 16.26 | 142.5 ± 18.89 |
| Change from Baseline to Week 6 | -31.3 ± 15.87 | -26.0 ± 16.62 |
To compare the change from baseline in mean sitting diastolic blood pressure (MSDBP) after 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.
| mmHg | Valsartan/Amlodipine/HCTZ | Losartan/HCTZ |
|---|---|---|
| Baseline | 98.6 ± 7.71 | 97.6 ± 7.88 |
| Week 6 | 85.1 ± 10.05 | 88.5 ± 11.36 |
| Change from Baseline to Week 6 | -13.6 ± 9.48 | -9.1 ± 10.03 |
To compare the percentage of patients achieving blood pressure control (defined as patients achieving MSSBP \< 140 mmHg and MSDBP \< 90 mmHg) after 3 and 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.
| cumulative percentage of patients | Valsartan/Amlodipine/HCTZ | Losartan/HCTZ |
|---|---|---|
| Week 3 | 30.5 | 15.3 |
| Week 6 | 61.5 | 47.1 |
To compare the percentage of treatment responders (defined as patients with MSSBP \< 140 mmHg or demonstrating a decrease from baseline of ≥ 20 mmHg) after 3 and 6 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.
| Cumulative percentage of responders | Valsartan/Amlodipine/HCTZ | Losartan/HCTZ |
|---|---|---|
| Week 3 | 65.3 | 34.3 |
| Week 6 | 87.0 | 71.5 |
To compare the change from baseline in MSSBP and MSDBP after 12 weeks of valsartan/amlodipine-based regimen with losartan-based regimen in patients with Stage 2 systolic hypertension.
| mmHg | Valsartan/Amlodipine/HCTZ | Losartan/HCTZ |
|---|---|---|
| Baseline MSSBP | 166.8 ± 7.03 | 168.5 ± 9.03 |
| Week 12 MSSBP | 130.8 ± 16.22 | 134.3 ± 19.41 |
| Change in MSSBP from baseline to Week 12 | -36.0 ± 16.08 | -34.2 ± 17.69 |
| Baseline MSDBP | 98.6 ± 7.71 | 97.6 ± 7.88 |
| Week 12 MSDBP | 82.5 ± 10.18 | 82.5 ± 11.43 |
| Change in MSDBP from baseline to Week 12 | -16.1 ± 9.91 | -15.1 ± 10.57 |
To assess the incidence of peripheral edema occurring with valsartan/amlodipine-based regimen versus losartan-based regimen in patients with Stage 2 systolic hypertension.
| cumulative percentage of patients | Valsartan/Amlodipine/HCTZ | Losartan/HCTZ |
|---|---|---|
| Week 3 | 0.8 | 0.8 |
| Week 6 | 0.8 | 0.8 |
| Week 9 | 1.3 | 0.8 |
| Week 12 | 2.9 | 4.5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valsartan / Amlodipine / HCTZ | — | 1/241 (0.4%) | 13/241 (5.4%) |
| Losartan / HCTZ | — | 2/247 (0.8%) | 8/247 (3.2%) |
| Event | Valsartan / Amlodipine / HCTZ | Losartan / HCTZ |
|---|---|---|
| Non-cardiac chest painGeneral disorders | 1/241 | 0/247 |
| Urinary tract infectionInfections and infestations | 0/241 | 1/247 |
| DizzinessNervous system disorders | 0/241 | 1/247 |
| Event | Valsartan / Amlodipine / HCTZ | Losartan / HCTZ |
|---|---|---|
| DizzinessNervous system disorders | 13/241 | 8/247 |
| Age Continuous(years) | Valsartan/Amlodipine/HCTZ | Losartan/HCTZ | Total |
|---|---|---|---|
| Mean | 55.0 ± 9.83 | 57.1 ± 9.69 | 56.1 ± 9.81 |
| Sex: Female, Male(Participants) | Valsartan/Amlodipine/HCTZ | Losartan/HCTZ | Total |
|---|---|---|---|
| Female | 102 | 111 | 213 |
| Male | 139 | 136 | 275 |
The record gives a start of Jul 2009, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Amlodipine · Hydrochlorothiazide
Isolated Systolic Hypertension →